ライフサイエンスコーパス: epoxide hydrolase

1 e epoxide ring-opening reaction catalyzed by epoxide hydrolase.

2 es, a reaction specificity characteristic of epoxide hydrolase.

3 ctivity of the P450s and regioselectivity of epoxide hydrolase.

4 identified inhibitors of the enzyme soluble epoxide hydrolase.

5 homogenates and is primarily metabolized by epoxide hydrolase.

6 yethanes are not accepted by known bacterial epoxide hydrolases.

7 and Tyr(381) is conserved among the soluble epoxide hydrolases.

8 kotoxin is only cytotoxic in the presence of epoxide hydrolases.

9 for epoxide selection by ionophore polyether epoxide hydrolases.

10 enes, cytochrome P-450 1A1 (CYP1A1) MspI and epoxide hydrolase 1 (EPHX1) Tyr113His, affect the associ

11 ) in N-acetyltransferase 1 (NAT1), NAT2, and epoxide hydrolase 1 (EPXH1).

12 as a set of rare and common variants in the Epoxide Hydrolase 2 (EPHX2) gene, in an initial sequenci

13 Because epoxide hydrolase 2 (EPHX2) was identified as a novel AN

14 utoantigens, and glutamate dehydrogenase and epoxide hydrolase-2 as additional autoantigens.

15 basal and inducible expression of microsomal epoxide hydrolase, a key enzyme in the detoxification of

16 e with the same stereochemistry as that from epoxide hydrolase action on the natural JH antipode.

17 xtensive hydrophobic contacts in the soluble epoxide hydrolase active site, and each urea carbonyl ox

18 The C-terminal domain, containing the epoxide hydrolase activity (Cterm-EH), is involved in th

19 ial cells and in this state does not exhibit epoxide hydrolase activity (i.e. conversion of LTA4 to L

20 oduct (FosX(Ml)) from M. loti has a very low epoxide hydrolase activity and even lower glutathione tr

21 Cif demonstrates epoxide hydrolase activity in vitro and requires a highl

22 produced in bacteria was shown to have high epoxide hydrolase activity in vitro.

23 allele demonstrated higher apparent soluble epoxide hydrolase activity in vivo.

24 ylation, protein phosphatase-1 activates the epoxide hydrolase activity of LTA-H.

25 peptidases, aldosterone synthase and soluble epoxide hydrolase, agonists of natriuretic peptide A and

26 tion; Tyr(465) is highly conserved among all epoxide hydrolases, and Tyr(381) is conserved among the

27 oli expressing recombinant Aspergillus niger epoxide hydrolase as the model enzyme for various enanti

28 se (GCS), UDP-glucuronosyltransferases (UGT),epoxide hydrolase, as well as a number of new genes.

29 r the first time we demonstrate that soluble epoxide hydrolase can bioactivate epoxides to diols that

30 In addition, soluble epoxide hydrolase catalyzes the hydrolysis of epoxyeicos

31 We show that cholesterol epoxide hydrolase (ChEH) metabolizes 5,6-EC into cholest

32 nd immunological evidence that the bacterial epoxide hydrolase Cif disrupts resolution pathways durin

33 Soluble epoxide hydrolase converts epoxyeicosatrienoic acids to

34 osynthetic pathway resembles other polyether epoxide hydrolases/cyclases of the MonB family, but SalB

35 Here, we show that a secreted P. aeruginosa epoxide hydrolase, cystic fibrosis transmembrane conduct

36 squalene epoxidases, triterpenoid synthases, epoxide hydrolases, cytochrome P450s, and UDP-glucosyltr

37 450s (P450s) and regioselective hydration by epoxide hydrolase determine the carcinogenic potency of

38 exene oxide, a known inhibitor of microsomal epoxide hydrolase, did not affect the production of meta

39 yme with two catalytic domains: a C-terminal epoxide hydrolase domain and an N-terminal phosphatase d

40 anti-inflammatory effects to the C-terminal epoxide hydrolase domain.

41 ucture of recombinant murine liver cytosolic epoxide hydrolase (EC 3.3.2.3) has been determined at 2.

42 The addition of purified epoxide hydrolase (EC 4.2.1.63) to the reconstituted enz

43 uctural underpinnings of the enzyme's unique epoxide hydrolase (EH) activity, involving Zn(2+), Y383,

44 s-dihydrodiol proximate carcinogens by human epoxide hydrolase (EH) and CYP1A1.

45 at Cif is capable of degrading the synthetic epoxide hydrolase (EH) substrate S-NEPC [(2S,3S)-trans-3

46 l sequence analysis suggested that Cif is an epoxide hydrolase (EH), but its sequence violates two st

47 A clone encoding a putative soluble epoxide hydrolase (EH-1), an enzyme which converts epoxi

48 Epoxide hydrolases (EH) catalyze the hydrolysis of epoxi

49 s the founding member of a distinct class of epoxide hydrolases (EHs) that triggers the catalysis-dep

50 Epoxide hydrolase either expressed from recombinant vacc

51 he hypotheses that inhibition of the soluble epoxide hydrolase enzyme can result in an increase in th

52 The soluble epoxide hydrolase enzyme catalyzes the hydrolysis of ant

53 urea-like compounds that inhibit the soluble epoxide hydrolase enzyme in mice and humans is examined.

54 pproach to increase EET levels is to inhibit epoxide hydrolase enzymes that are responsible for conve

55 TNF receptor 3 '-flanking region gene, human epoxide hydrolase (EPHX), human growth/differentiation f

56 he glutathione S-transferases (GSTs) and the epoxide hydrolases (EPHX).

57 Microsomal epoxide hydrolase (EPHX1) catalyzes hydration reactions

58 on approach identified four genes-microsomal epoxide hydrolase (EPHX1), latent transforming growth fa

59 termine whether genetic variation in soluble epoxide hydrolase (EPHX2) was associated with the risk o

60 tathione S-transferases (GST) and microsomal epoxide hydrolase (EPXH).

61 summary, in mice, TSO increases Cyp2b10 and epoxide hydrolase expression in mice via CAR, and potent

62 le comparisons, only one polymorphism in the epoxide hydrolase family 2 locus remained significantly

63 Here, the epoxide hydrolase from Agrobacterium radiobacter AD1 (Ec

64 CIMB 13064, and haloalcohol dehalogenase and epoxide hydrolase from Agrobacterium radiobacter AD1.

65 rt the in vitro characterization of SgcF, an epoxide hydrolase from the C-1027 biosynthetic gene clus

66 association of polymorphisms in the soluble epoxide hydrolase gene (EPHX2) with incident ischemic st

67 ong women AA for rs2234922 in the microsomal epoxide hydrolase gene, EPHX1 (OR = 1.77, 95% CI: 1.06,

68 lic compensation for the loss of the soluble epoxide hydrolase gene.

69 ce with a targeted disruption of the soluble epoxide hydrolase gene.

70 erritin (heavy and light chains), microsomal epoxide hydrolase, glutathione S-transferase, and gamma-

71 addition of catalase, superoxide dismutase, epoxide hydrolase, glutathione, or ascorbic acid.

72 d evolution to a variety of enzymes, such as epoxide hydrolase, glyphosate N-acetyltransferase, xylan

73 ic system that was catalysed by limonene-1,2-epoxide hydrolase, had an intracellular nature and was c

74 rea inhibitors complexed with murine soluble epoxide hydrolase have been determined by x-ray crystall

75 ally active, as assessed by the induction of epoxide hydrolase, heme oxygenase-1, and glutamate cyste

76 2b10, NAD(P)H:quinone oxidoreductase (Nqo1), epoxide hydrolase, heme oxygenase-1, UDP-glucuronosyl-tr

77 Human soluble epoxide hydrolase (hsEH) metabolizes a variety of epoxid

78 erminal methionine PTS1 (SKM), human soluble epoxide hydrolase (hsEH), shows both peroxisomal and cyt

79 first direct evidence for a role for soluble epoxide hydrolase in blood pressure regulation and ident

80 cificity that implicates participation of an epoxide hydrolase in converting epoxyalcohol to triol.

81 Although disruption of soluble epoxide hydrolase in female mice had minimal effects on

82 Cyp2b10 and epoxide hydrolase induction by TSO was decreased in live

83 Treatment with soluble epoxide hydrolase inhibitor significantly reduces the ac

84 The epoxide hydrolase inhibitor, 4-phenylchalone oxide, whic

85 ) are coadministered with a low-dose soluble epoxide hydrolase inhibitor, EDPs are stabilized in circ

86 beneficial effects of several potent soluble epoxide hydrolase inhibitors (sEHIs) in different models

87 We also show that soluble epoxide hydrolase inhibitors, which elevate endogenous E

88 quinone reductase, glucuronosyltransferases, epoxide hydrolase) is a major strategy for reducing the

89 Juvenile hormone epoxide hydrolase (JHEH) has attracted great interest be

90 During lasalocid A biosynthesis, an epoxide hydrolase, Lsd19, converts the bisepoxy polyketi

91 olymorphisms in the gene encoding microsomal epoxide hydrolase (mEH) among 464 cases diagnosed with f

92 Microsomal epoxide hydrolase (MEH) catalyzes the addition of water

93 Microsomal epoxide hydrolase (mEH) is a bifunctional membrane prote

94 Microsomal epoxide hydrolase (mEH) is a conserved enzyme that is kn

95 Microsomal epoxide hydrolase (MEH) is a member of the alpha/beta-hy

96 es have suggested that the enzyme microsomal epoxide hydrolase (mEH) is able to mediate sodium-depend

97 Microsomal epoxide hydrolase (mEH) plays a central role in xenobiot

98 The microsomal epoxide hydrolase (mEH) plays a significant role in the

99 Two of these genes, SM20 and microsomal epoxide hydrolase (mEH), are previously described genes.

100 immunosuppression is CYP1B1- and microsomal epoxide hydrolase (mEH)-dependent, demonstrating that th

101 Microsomal epoxide hydrolase (mEH, EPHX1) is a critical biotransfor

102 her polymorphisms in the gene for microsomal epoxide hydrolase (mEPHX), an enzyme involved in this pr

103 Soluble epoxide hydrolase metabolizes epoxyeicosatrienoic acids

104 ion enzymes [e.g., glutathione transferases, epoxide hydrolase, NAD(P)H: quinone reductase, and glucu

105 Both female soluble epoxide hydrolase-null and wild-type female mice also ha

106 Finally, the soluble epoxide hydrolase-null mice show a survival advantage fo

107 Systolic blood pressure of male soluble epoxide hydrolase-null mice was lower compared with wild

108 wo independently derived colonies of soluble epoxide hydrolase-null mice were compared.

109 rienoic acids was markedly lower for soluble epoxide hydrolase-null versus wild-type mice of both sex

110 respectively) in the cytochrome P450/soluble epoxide hydrolase pathway.

111 e, reconstituted CYP1A1-Ile462 together with epoxide hydrolase produced 7,8- and 9,10-dihydrodiols at

112 AAG with cloned CYP3A4 and cloned microsomal epoxide hydrolase produced metabolites 2 and 4, with gre

113 Ephx2 gene disruption eliminated soluble epoxide hydrolase protein expression and activity in liv

114 e report findings that inhibition of soluble epoxide hydrolase reduces inflammation, oxidative stress

115 Hydrolysis of the toxic epoxide by epoxide hydrolases represents the major biological detox

116 Metabolism of these compounds by epoxide hydrolases results in the formation of compounds

117 n of dual-target ligands that target soluble epoxide hydrolase (sEH) and the peroxisome proliferator-

118 Inhibitors of soluble epoxide hydrolase (sEH) are under evaluation for their u

119 Here we identify soluble epoxide hydrolase (sEH) as a key enzyme that initiates p

120 Using human soluble epoxide hydrolase (sEH) as a model antigen, we were able

121 l trials combined with inhibition of soluble epoxide hydrolase (sEH) as anti-inflammatory strategy pr

122 Soluble epoxide hydrolase (sEH) catalyzes the conversion of epox

123 Mammalian soluble epoxide hydrolase (sEH) converts epoxides to their corre

124 enetic ablation or inhibition of the soluble epoxide hydrolase (sEH) enzyme led to increased levels o

125 The X-ray crystal structure of human soluble epoxide hydrolase (sEH) has been determined at 2.6 A res

126 hydroxyeicosatrienoic acid (DHET) by soluble epoxide hydrolase (sEH) in mammalian tissues, and inhibi

127 The role of soluble epoxide hydrolase (sEH) in the central control of blood

128 tion of endogenous epoxide levels by soluble epoxide hydrolase (sEH) in the endothelium represents an

129 sistent with increased expression of soluble epoxide hydrolase (sEH) in the SHR renal microsomes and

130 revious study showed that inhibiting soluble epoxide hydrolase (sEH) increased EET concentration and

131 We hypothesized that soluble epoxide hydrolase (SEH) inhibition would improve renal v

132 We tested the use of soluble epoxide hydrolase (sEH) inhibitors as a means to enhance

133 tandem mass spectrometric method for soluble epoxide hydrolase (sEH) inhibitors in rat hepatic micros

134 the urea were prepared and tested as soluble epoxide hydrolase (sEH) inhibitors.

135 Soluble epoxide hydrolase (sEH) is a bifunctional enzyme located

136 Soluble epoxide hydrolase (sEH) is a bifunctional enzyme with tw

137 Soluble epoxide hydrolase (sEH) is a cytosolic enzyme whose inhi

138 Here, we demonstrate that the soluble epoxide hydrolase (sEH) is a key pharmacologic target fo

139 Inhibition of the mammalian soluble epoxide hydrolase (sEH) is a promising new therapy in th

140 Soluble epoxide hydrolase (sEH) is a therapeutic target for trea

141 Soluble epoxide hydrolase (sEH) is an emerging therapeutic targe

142 Soluble epoxide hydrolase (sEH) is an enzyme involved in drug me

143 Inhibition of soluble epoxide hydrolase (sEH) is hypothesized to lead to an in

144 Soluble epoxide hydrolase (sEH) is inhibited by electrophilic li

145 Soluble epoxide hydrolase (sEH) is involved in the metabolism of

146 The soluble epoxide hydrolase (sEH) is involved in the metabolism of

147 Soluble epoxide hydrolase (sEH) is the major enzyme responsible

148 cids (EETs) from the cytochrome P450/soluble epoxide hydrolase (sEH) pathway are important eicosanoid

149 Soluble epoxide hydrolase (sEH) plays a key role in the metaboli

150 The soluble epoxide hydrolase (sEH) plays a significant role in the

151 Soluble epoxide hydrolase (sEH) plays an important role in the m

152 rvations that urea inhibitors of the soluble epoxide hydrolase (sEH) reduce blood pressure in spontan

153 ids (EFAs) through inhibition of the soluble epoxide hydrolase (sEH) reduces pain.

154 xy-fatty acids through inhibition of soluble epoxide hydrolase (sEH) was shown to reduce diabetic neu

155 The EPXH2 gene encodes for the soluble epoxide hydrolase (sEH), a homodimeric enzyme with each

156 The gene EPXH2 encodes for the soluble epoxide hydrolase (sEH), an enzyme involved in the regul

157 EPHX2 encodes for soluble epoxide hydrolase (sEH), an important enzyme in the meta

158 cytochrome P450 epoxygenases and the soluble epoxide hydrolase (sEH), and targeting the latter is an

159 ne, and because its protein product, soluble epoxide hydrolase (sEH), converts bioactive epoxides of

160 ered in the N-terminal domain of the soluble epoxide hydrolase (sEH), opening a new branch of fatty a

161 Inhibition of soluble epoxide hydrolase (SEH), the enzyme responsible for degr

162 Furthermore, inhibitors of soluble epoxide hydrolase (sEH), the enzyme that metabolizes EET

163 ET levels are typically regulated by soluble epoxide hydrolase (sEH), the major enzyme degrading EETs

164 sible for EETs synthesis, as well as soluble epoxide hydrolase (sEH), which metabolizes EETS to DHETs

165 examined the effect of FABPs on the soluble epoxide hydrolase (sEH)-mediated conversion of EETs to d

166 tyl-ureido-dodecanoic acid (AUDA), a soluble epoxide hydrolase (sEH)-specific inhibitor, EETs increas

167 peutic target for pain is the enzyme soluble epoxide hydrolase (sEH).

168 supposedly less active diols by the soluble epoxide hydrolase (sEH).

169 for vasorelaxation and inhibition of soluble epoxide hydrolase (sEH).

170 s inhibitors of the human and murine soluble epoxide hydrolase (sEH).

171 ot a result of altered expression of soluble epoxide hydrolase (sEH).

172 rings and for in vitro inhibition of soluble epoxide hydrolase (sEH).

173 pyridine and an urea moiety as novel soluble epoxide hydrolase (sEH)/5-lipoxygenase (5-LO) dual inhib

174 of EETs is limited primarily by the soluble epoxide hydrolase (sEH, EPHX2), which metabolizes EETs t

175 iated EET biosynthesis and decreased soluble epoxide hydrolase (sEH, Ephx2)-mediated EET hydrolysis o

176 Soluble epoxide hydrolase (sEH; encoded by Ephx2) deficiency and

177 Inhibitors of the soluble epoxide hydrolase (sEHI) elevated and stabilized the lev

178 ipid-derived chemotactic activity is soluble epoxide hydrolase sensitive, consistent with hepoxilin A

179 ylstyrene oxide in the active site of murine epoxide hydrolase show two possible binding conformation

180 eficial biofilm was engineered to produce an epoxide hydrolase so that it efficiently removes the env

181 opropylene 1,2-oxide (TCPO), an inhibitor of epoxide hydrolase, suggesting that P450 enzymes exhibite

182 Like Cif, aCif is an epoxide hydrolase that carries an N-terminal secretion s

183 in Pseudomonas aeruginosa, Cif is a secreted epoxide hydrolase that is transcriptionally regulated by

184 To confirm that EH-1 encodes an epoxide hydrolase, the recombinant EH-1 protein produced

185 Epoxide hydrolases therefore have potential synthetic ap

186 pathway whereby 11,12-EET is converted by an epoxide hydrolase to 11,12-DHET, which then undergoes tw

187 oxicity of leukotoxin, which is activated by epoxide hydrolase to its toxic diol.

188 s that can be further metabolized by soluble epoxide hydrolase to the corresponding dihydroxyeicosatr

189 Pseudomonas aeruginosa secretes an epoxide hydrolase virulence factor that reduces the apic

190 rodiol enriched in S,S-form, suggesting that epoxide hydrolase was highly regioselective.

191 Previously, Cif, an epoxide hydrolase, was shown to be regulated at the tran

192 ressed human and mouse P450s 1A1 and 1A2 and epoxide hydrolase were used to characterize the stereose

193 sis-related protein 1.2, heme oxygenase, and epoxide hydrolase) were demonstrated to be regulated by

194 mic substrate could be exploited to engineer epoxide hydrolases with improved regio- and/or enantiosp

195 s (YknXYZ), non-haem bromoperoxidase (YdjP), epoxide hydrolase (YfhM) and three small peptides with s